1. Home
  2. RWAY vs NERV Comparison

RWAY vs NERV Comparison

Compare RWAY & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Runway Growth Finance Corp.

RWAY

Runway Growth Finance Corp.

HOLD

Current Price

$5.45

Market Cap

226.3M

Sector

N/A

ML Signal

HOLD

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$4.47

Market Cap

210.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RWAY
NERV
Founded
2015
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
226.3M
210.1M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
RWAY
NERV
Price
$5.45
$4.47
Analyst Decision
Buy
Buy
Analyst Count
6
2
Target Price
$9.50
$10.50
AVG Volume (30 Days)
646.1K
358.2K
Earning Date
05-07-2026
05-01-2026
Dividend Yield
21.54%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$41,175,600.00
Revenue This Year
$1.26
N/A
Revenue Next Year
$1.25
N/A
P/E Ratio
$5.70
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.19
$1.76
52 Week High
$11.20
$12.46

Technical Indicators

Market Signals
Indicator
RWAY
NERV
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
RWAY
NERV

About RWAY Runway Growth Finance Corp.

Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and UK, Canada, Netherlands, with the majority of its portfolio invested in the United States. The company's investment objective is to maximize its total return to its stockholders through current income on its loan portfolio, and secondarily through capital gain on its warrants and other equity positions.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Share on Social Networks: